Try our beta test site
Trial record 7 of 12 for:    dart cancer

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT02834013
First received: July 13, 2016
Last updated: March 23, 2017
Last verified: February 2017
  Purpose
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

Condition Intervention Phase
Acinar Cell Carcinoma
Adrenal Cortex Carcinoma
Adrenal Gland Pheochromocytoma
Anal Canal Neuroendocrine Carcinoma
Anal Canal Undifferentiated Carcinoma
Appendix Mucinous Adenocarcinoma
Bladder Adenocarcinoma
Bronchioloalveolar Carcinoma
Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Cholangiocarcinoma
Chordoma
Colorectal Squamous Cell Carcinoma
Endometrioid Adenocarcinoma
Esophageal Neuroendocrine Carcinoma
Esophageal Undifferentiated Carcinoma
Extrahepatic Bile Duct Carcinoma
Fallopian Tube Adenocarcinoma
Fibromyxoid Tumor
Gastric Neuroendocrine Carcinoma
Gastric Squamous Cell Carcinoma
Giant Cell Carcinoma
Intestinal Neuroendocrine Carcinoma
Intrahepatic Cholangiocarcinoma
Lung Carcinoid Tumor
Lung Sarcomatoid Carcinoma
Major Salivary Gland Carcinoma
Malignant Odontogenic Neoplasm
Malignant Peripheral Nerve Sheath Tumor
Malignant Skin Neoplasm
Malignant Testicular Sex Cord-Stromal Tumor
Metastatic Malignant Neoplasm of Unknown Primary Origin
Mixed Mesodermal (Mullerian) Tumor
Mucinous Adenocarcinoma
Mucinous Cystadenocarcinoma
Nasal Cavity Adenocarcinoma
Nasal Cavity Carcinoma
Nasopharyngeal Carcinoma
Nasopharyngeal Papillary Adenocarcinoma
Nasopharyngeal Undifferentiated Carcinoma
Oral Cavity Carcinoma
Oropharyngeal Undifferentiated Carcinoma
Ovarian Adenocarcinoma
Ovarian Germ Cell Tumor
Ovarian Mucinous Adenocarcinoma
Ovarian Squamous Cell Carcinoma
Pancreatic Acinar Cell Carcinoma
Pancreatic Neuroendocrine Carcinoma
Paraganglioma
Paranasal Sinus Adenocarcinoma
Paranasal Sinus Carcinoma
Parathyroid Gland Carcinoma
Pituitary Gland Carcinoma
Placental Choriocarcinoma
Placental-Site Gestational Trophoblastic Tumor
Primary Peritoneal High Grade Serous Adenocarcinoma
Pseudomyxoma Peritonei
Scrotal Squamous Cell Carcinoma
Seminal Vesicle Adenocarcinoma
Seminoma
Serous Cystadenocarcinoma
Small Intestinal Adenocarcinoma
Small Intestinal Squamous Cell Carcinoma
Spindle Cell Neoplasm
Squamous Cell Carcinoma of the Penis
Teratoma With Malignant Transformation
Testicular Non-Seminomatous Germ Cell Tumor
Thyroid Gland Carcinoma
Tracheal Carcinoma
Transitional Cell Carcinoma
Undifferentiated Gastric Carcinoma
Ureter Adenocarcinoma
Ureter Squamous Cell Carcinoma
Urethral Adenocarcinoma
Urethral Squamous Cell Carcinoma
Vaginal Adenocarcinoma
Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Vulvar Adenocarcinoma
Vulvar Squamous Cell Carcinoma
Procedure: Biospecimen Collection
Biological: Ipilimumab
Biological: Nivolumab
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • ORR defined as confirmed and unconfirmed complete and partial response, assessed by RECIST 1.1 [ Time Frame: Up to 10 years ]

Secondary Outcome Measures:
  • Best response calculated from the sequence of RECIST 1.1 and immune-related response criteria (irRC) objectives [ Time Frame: Up to 10 years ]
    Assuming 16 eligible patients per stratum, this will be sufficient to estimate each binary version of this endpoint within +/- 25% (95% confidence interval).

  • Clinical benefit rate defined as complete response, partial response, or stable disease, estimated using both RECIST and irRC [ Time Frame: 6 months ]
    Assuming 16 eligible patients per stratum, this will be sufficient to estimate each binary version of this endpoint within +/- 25% (95% confidence interval).

  • Incidence of adverse events graded by NCI CTCAE version 4.0 [ Time Frame: Up to 10 years ]
    Assuming 16 eligible patients per stratum, this will be sufficient to estimate each binary version of this endpoint within +/- 25% (95% confidence interval).

  • OS, estimated using both RECIST and irRC [ Time Frame: From date of registration to date of death due to any cause, assessed up to 10 years ]
    Assuming 16 eligible patients per stratum, this will be sufficient to estimate each binary version of this endpoint within +/- 25% (95% confidence interval).

  • PFS, estimated using both RECIST and irRC [ Time Frame: From date of registration to date of first documentation of progression or symptomatic deterioration or death, assessed up to 10 years ]
    Assuming 16 eligible patients per stratum, this will be sufficient to estimate each binary version of this endpoint within +/- 25% (95% confidence interval).


Estimated Enrollment: 334
Study Start Date: January 2017
Estimated Primary Completion Date: August 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (nivolumab, ipilimumab)
Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 60 minutes on day 1. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
Procedure: Biospecimen Collection
Undergo optional collection of biopsy tissue and blood
Biological: Ipilimumab
Given IV
Other Names:
  • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
  • Yervoy
Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.

SECONDARY OBJECTIVES:

I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free survival (PFS), clinical benefit rate; and to estimate immune-related ORR (irORR), and immune-related PFS (irPFS) by unidimensional immune-related response criteria.

III. To collect specimens for banking for use in future correlative biomarker research studies.

OUTLINE:

Patients receive nivolumab intravenously (IV) over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 60 minutes on day 1. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 10 years from registration.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically confirmed rare cancer and/or cancer of unknown primary, that did not have a match to a molecularly-guided therapy on EAY131 "National Cancer Institute (NCI)-Molecular Analysis for Therapy Choice (MATCH)" protocol or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations per EAY131, "NCI-MATCH"

    • All baseline assessments must have been completed within 28 days prior to registration
  • Patients that do not qualify for one of the histologic cohorts may be considered for registration in the "Not Otherwise Categorized" Rare Tumors cohort with confirmation of the study chairs via email
  • Patients that are determined to have a rare cancer with unknown primary site are eligible provided that there is histologic documentation of metastatic malignancy with no discernible primary site identified from histopathologic review, physical exam and associated cross-sectional imaging of the chest, abdomen, and pelvis
  • Patients must have a diagnostic quality computed tomography (CT) scan or magnetic resonance imaging (MRI), performed within 28 days prior to registration, which demonstrates measurable disease, as defined in RECIST v. 1.1; all disease must be assessed and documented on the S1609 Baseline Tumor Assessment Form
  • No other prior malignancy is allowed except for the following:

    • Adequately managed stage I or II cancer from which the patient is currently in complete remission
    • Any other cancer from which the patient has been disease free for five years
    • Adequately managed stage I or II follicular thyroid or prostate cancer is also eligible, wherein patient is not required to be in complete remission
  • Patients who have received prior anti-CTLA4 or other anti-PD-1/anti-PD-L1 therapy, not both, provided that it is completed >= 4 weeks prior to registration for monoclonal therapy, >= 8 weeks prior to registration if therapy involved immunestimulatory monoclonal antibody (mAb)s, and >= 28 days for all other immunotherapy
  • Patients who had prior immune-related adverse event (grade 3 or higher immune-related pneumonitis, hepatitis, colitis, endocrinopathy) with prior immunotherapy (e.g. cancer vaccine, cytokine, etc.) are not eligible
  • Patients with clinically controlled thyroiditis or pituitary disorders on stable replacement therapy are eligible
  • Patients are not eligible if they have had or are planned for solid organ transplant; patients who have received allogeneic hematopoietic stem cell transplant are eligible if the transplant occurred at least 90 days prior to registration, patient has no prior acute graft versus host disease (GVHD), and within 48 hours of registration, patient demonstrates at least 90% engraftment, defined as: absolute neutrophil count (ANC) >= 500 mcl, measured over 3 consecutive days or 1 day with an ANC >= 1,000 mcl, or platelets >= 50,000 mcl measured, wherein the patient did not receive any platelet transfusions within 7 days prior to laboratory assessment, patients with autoimmune disease who are otherwise eligible under criterion 5.3 k must not have received steroid and immunosuppressive therapy within 28 days prior to registration
  • Patients with brain metastases or primary brain tumors must have completed treatment, surgery or radiation therapy >= 28 days prior to registration and have stable disease at time of registration; metastatic brain parenchymal disease must have been treated and patient must be off steroids for 7 days prior to registration
  • Patients must not currently be receiving any other investigational agents or any other systemic anti-cancer therapy (including radiation); in event patient recently received any other systemic anti-cancer therapy, patient must be off therapy at least 7 days prior to registration and any therapy-induced toxicity must have recovered to =< grade 1
  • Patients must have a Zubrod performance status of 0-2
  • ANC >= 1,000/mcL
  • Platelets >= 75,000/mcL
  • Hemoglobin >= 8 g/dL
  • Total bilirubin =< 3.0 x institutional upper limit of normal (IULN) or for documented/suspected Gilbert's disease
  • Total bilirubin =< 3.0 x IULN
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 3 x IULN
  • Serum creatinine =< 2.0 IULN
  • Creatinine clearance (CrCl) >= 50 mL/min., as estimated by the Cockcroft and Gault formula; estimated creatinine clearance is based on actual body weight
  • Patients must have adequate thyroid function, as evidenced by thyroid-stimulating hormone (TSH), free thyroxine (T4) serum tests demonstrating values within the normal range, within 28 days prior to registration; Note: TSH, with reflex T4 is allowable if per institutional standard; otherwise, both TSH and free-T4 must be obtained
  • Patients must have adequate adrenal axis function, as evidenced by Adrenocorticotropic Hormone (ACTH) values within the normal ranges, within 28 days prior to registration
  • Females of childbearing potential must have negative serum pregnancy test 14 days prior to registration and agree to use birth control throughout study and for 23 weeks after completion of protocol therapy; patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
  • Men of reproductive potential must have agreed to use birth control throughout the study and for 31 weeks after completion of protocol therapy; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (vasectomy); however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he is responsible for beginning contraceptive measures
  • Patients must not have known active hepatitis B virus (HBV) or hepatitis virus (HCV) infection at time of registration; patients with HBV or HCV that have an undetectable viral load, or in the opinion of the treating investigator is well-controlled, are eligible
  • Patients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration:

    1. Cluster of differentiation (CD)4+ cell count greater or equal to 250 cells/mm^3
    2. If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; once daily combinations that use pharmacologic boosters may not be used
    3. No history of non-malignancy acquired immunodeficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts
    4. Probable long-term survival with HIV if cancer were not present
  • Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, immunosuppressive drugs, or corticosteroids with doses higher than prednisone 10mg or equivalent). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Autoimmune diseases include but are not limited to autoimmune hepatitis, inflammatory bowel disease, multiple sclerosis, vasculitis, or glomerulonephritis; patients with well-controlled systemic lupus erythematous or rheumatoid arthritis may be eligible after communication with the study chairs at S1609SC@swog.org; vitiligo, alopecia, hypothyroidism on stable doses of thyroid replacement therapy, psoriasis not requiring systemic therapy within the past 3 years is permitted; short-term steroid premedication for contrast allergy is permitted
  • Patients must not have any uncontrolled intercurrent illness including (not limited to): symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA] III/IV), unstable angina pectoris or coronary angioplasty, or stenting within 24 weeks prior to registration, unstable cardiac arrhythmia (ongoing cardiac dysrhythmias of NCI Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4 grade >= 2), known psychiatric illness that would limit study compliance, intra-cardiac defibrillators, known cardiac metastases, or abnormal cardiac valve morphology (>= grade 3)

    • Note: Echocardiography (ECHO) and electrocardiogram (EKG) are clinically indicated at baseline for any patient with a history of CHF or a risk due to underlying cardiovascular disease or prior exposure to cardiotoxic drugs; if patient has any evidence of CHF, MI, cardiomyopathy, or myositis cardiac evaluation (NYHA I/II) patient, cardiology consultation is also clinically indicated at baseline (in addition to ECHO and EKG), with creatine phosphokinase (CPK) and troponin testing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02834013

  Show 380 Study Locations
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: Sandip Patel Southwest Oncology Group
  More Information

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02834013     History of Changes
Other Study ID Numbers: NCI-2016-01041
NCI-2016-01041 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
S1609
S1609 ( Other Identifier: SWOG )
S1609 ( Other Identifier: CTEP )
U10CA180888 ( US NIH Grant/Contract Award Number )
Study First Received: July 13, 2016
Last Updated: March 23, 2017

Additional relevant MeSH terms:
Neoplasms
Neoplasms, Germ Cell and Embryonal
Nasopharyngeal Neoplasms
Carcinoid Tumor
Neuroendocrine Tumors
Ovarian Neoplasms
Stomach Neoplasms
Salivary Gland Neoplasms
Neoplasms, Second Primary
Nerve Sheath Neoplasms
Testicular Neoplasms
Skin Neoplasms
Trophoblastic Neoplasms
Carotid Body Tumor
Thyroid Neoplasms
Sex Cord-Gonadal Stromal Tumors
Trophoblastic Tumor, Placental Site
Pituitary Neoplasms
Parathyroid Neoplasms
Mixed Tumor, Mullerian
Neoplasms, Unknown Primary
Odontogenic Tumors
Paranasal Sinus Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on March 24, 2017